| Digestive System Adenosquamous Carcinoma studied in …STUDIED_INderived13 of 13show fewer |
|---|
| → studied in | NCT07621718Phase 3 · recruiting Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) · condition mapped ONTOLOGY_EXACT · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858334Phase 2 · recruiting APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation · condition mapped ONTOLOGY_EXACT · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07491445Phase 3 · recruiting Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07805954Phase 3 · recruiting Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04340141Phase 3 · active not recruiting Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer · condition mapped ONTOLOGY_EXACT · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07573215approved for marketing Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04157127Phase 1 · recruiting Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04896073Phase 2 · completed Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) · condition mapped ALIAS · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07665684Phase 1/Phase 2 · not yet recruiting Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer · condition mapped ALIAS · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05419479Phase 1/Phase 2 · suspended Switch Maintenance in Pancreatic · condition mapped ALIAS · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06115499Phase 2/Phase 3 · active not recruiting The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer · condition mapped ONTOLOGY_EXACT · 13 trials mapped (9 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06923020enrolling by invitation Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Cancer. · condition mapped ONTOLOGY_EXACT · 13 trials mapped (9 active) | — | — | Esophageal Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01093222Phase 2 · completed Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma · condition mapped ALIAS · 13 trials mapped (9 active) | — | — | Gallbladder Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |